Top Markets
Coin of the day
Revive Therapeutics Ltd. Revive Therapeutics Ltd.

Revive Therapeutics Ltd.

RVV
株式のランク #32620
Revive Therapeutics Ltd., a life sciences firm, specializes in the research and... Revive Therapeutics Ltd., a life sciences firm, specializes in the research and development of treatments for rare disorders and infectious diseases. The company’s pharmaceutical pipeline features a cannabinoid portfolio focused on rare inflammatory ailments. Currently, it is advancing Bucillamine through a Phase 3 clinical study for infectious diseases like influenza and COVID-19. Its psychedelic programs include Psilocybin, undergoing a Phase 1 clinical study for methamphetamine use disorder, and Psilocin, which is being investigated for applications in depression, anxiety, bipolar disorder, bulimia, anorexia nervosa, and other related conditions. Additionally, Revive is exploring cannabidiol for autoimmune hepatitis and for addressing ischemia and reperfusion injury following organ transplantation. The company has forged several significant research collaborations: with PharmaTher Inc. for psilocybin development in cancer treatment, the discovery of other psychedelic compound applications, and a psilocybin microneedle patch; with North Carolina State University to develop a biosynthetic psilocybin based on a natural enzymatic platform; with the University of California, San Francisco, to investigate Bucillamine for severe COVID-19; and with the University of Health Sciences Antigua for clinical research into psychedelics. Established in 2012, Revive Therapeutics Ltd. is headquartered in Toronto, Canada.
株価
$0.02201811
時価総額
$9.59M
変化(1日)
0.00%
変化(1年)
52.14%
CA
取引 Revive Therapeutics Ltd. (RVV)

カテゴリー

Revive Therapeutics Ltd.(RVV)の収益
Aug 2026 時点の収益 TTM: 0
Revive Therapeutics Ltd. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Revive Therapeutics Ltd. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。